ArticleThe British journal of ophthalmology2007
Tacrolimus immunosuppression in high-risk corneal grafts.
Article in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 98 citations in OpenAlex.
- Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.BMC ophthalmology · 2024Trial
- Indications and long-term outcomes of repeat optical penetrating keratoplasty.Indian journal of ophthalmology · 2026Article
- Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience.Ophthalmology science · 2026Article
- Topical Tacrolimus in the Management of High-Risk Keratoplasty: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Immunology in corneal transplantation-From homeostasis to graft rejection.Transplantation reviews (Orlando, Fla.) · 2025Review
- Influential Factors and Outcome of High-Risk Keratoplasty in a Tertiary Referral Corneal Center: A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Article
- Outcomes following tacrolimus systemic immunosuppression for penetrating keratoplasty in infants and young children.Eye (London, England) · 2022Article
- Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study.BMC ophthalmology · 2022Article
- Bone Morphogenetic Protein 4 (BMP4) Enhances the Differentiation of Human Induced Pluripotent Stem Cells into Limbal Progenitor Cells.Current issues in molecular biology · 2021Article
- Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model.Pharmaceutics · 2021Article
- Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop.Pharmaceutics · 2021Article
- Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021Review
- Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Current and emerging therapies for corneal neovascularization.The ocular surface · 2018Review
- Update on the Management of High-Risk Penetrating Keratoplasty.Current ophthalmology reports · 2017Article
- Topical tacrolimus in anterior segment inflammatory disorders.Eye and vision (London, England) · 2017Review
- Systemic Immunosuppression in High-Risk Penetrating Keratoplasty: A Systematic Review.Journal of clinical medicine research · 2016Review
- Corneal Allograft Rejection: Immunopathogenesis to Therapeutics.Journal of clinical & cellular immunology · 2013Article
- Adverse effects of systemic immunosuppression in keratolimbal allograft.Journal of ophthalmology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnlike the immune privilege enjoyed by low-risk corneal grafts, high-risk corneal grafts experience rejection rates comparable to liver and kidney transplants. Systemic immunosuppression reduces the risk of rejection in high-risk corneal grafts.
methodsSystemic tacrolimus, a specific T cell inhibitor, was used at a mean daily dose of 2.5 mg to immunosuppress 43 patients undergoing high-risk corneal transplantation. Immunosuppression was continued for a period of 18-24 months after the high-risk corneal graft.
resultsDuring a mean follow-up period of 33.7 months, clarity of the graft was maintained in 65% of patients. Eight patients experienced rejection episodes while on tacrolimus, and this led to graft failure in five patients.
conclusionTacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in patients with high-risk keratoplasty compared with other series where similar immunosuppression was not used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.